By John Ingold An obscure Colorado board took an unprecedented step last week in an attempt to control the prices that patients pay for their medicines. … “The board has […]
By Luke Zarzecki The Colorado Prescription Drug Affordability Board voted Friday (Oct. 3) to set an upper payment limit (UPL) on Amgen’s Enbrel that will take effect on Jan. 1,
By Celine Castronuovo Amgen Inc.‘s blockbuster biologic Enbrel will be the first product to face a state-imposed health plan payment cap under a landmark vote by a key Colorado affordability
October 3, 2025 Tiffany Westrich-Robertson, EACH/PIC Coalition founder and person living with an autoimmune condition, issued the following statement on today’s upper payment limit decision: “We are disappointed that the
The EACH/PIC Coalition submitted comments to the Colorado PDAB in advance of their fourth rulemaking hearing to implement an upper payment limit for Enbrel. The letter urges the board not
The EACH/PIC Coalition submitted a comment letter to the Washington Prescription Drug Affordability Board (PDAB) sharing best practices on patient engagement and giving specific feedback on draft surveys released by
The EACH/PIC Coalition submitted a comment letter to the Minnesota Prescription Drug Affordability Board (PDAB) providing input for the board on patient engagement, sharing best practices and lessons learned in
The EACH/PIC Coalition submitted comments to the Oregon PDAB in advance of their September meeting on policies proposed for the annual report to the Oregon legislature. The letter applauded the
The EACH/PIC Coalition submitted comment letters to the Maryland PDAB, providing input and feedback on the dossiers developed as part of the cost review process for Ozempic and Trulicity. The
The EACH/PIC Coalition submitted a comment letter to the Maryland Prescription Drug Affordability Stakeholder Council (PDASC), providing input on determining appropriate policy interventions to address affordability concerns around Jardiance and
